10-03-2020
Panchenko Vladimir / Shutterstock.com
A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Par Pharmaceutical, Merck, Glenmark, generics, antitrust, pay-for-delay, competition, settlement, Zetia
MSD and Glenmark appeal pay-for-delay Zetia dispute
07-01-2021
Glenmark becomes fifth generic to be charged with US antitrust violations
02-07-2020
AG advises CJEU to uphold €94 million pay-for-delay fine
05-06-2020
Retirees interest group supports California’s pay-for-delay ban
10-03-2020
CJEU issues clarification on UK’s pay-for-delay generics ruling
31-01-2020
California outlaws pay-for-delay deals
09-10-2019
